Treating anterior vaginal wall prolapse with polypropylene mesh via the transoburator route minimizing the complications with the use of preventing measures. A prospective study with 2-year follow-up.

AIM: Our objectives were to evaluate the efficacy of the Perigee™ transoburator (TOT) mesh kit (American Medical Systems [AMS]-Minnetonka, MN, USA) in the treatment of ≥ stage 2 symptomatic AVP following a 2-year follow-up and to discuss the role of the pre-, peri- and postoperative measures taken to prevent complications METHODS: A total of 50 patients were eligible and were subjected to AVP surgical treatment with the use of the Perigee™ system. All patients were followed-up at 4 weeks, 2, 6, 12 and 24 months. Our primary objective was treatment success and efficacy after anatomical examination of the patient at the 24-month follow-up. Efficacy was defined as ≤ stage I AVP. All patients completed the 24-month follow-up. Our secondary objective was to examine the complication rates in relation to the use of preventative measures. RESULTS: The proportion of patients with II to III stage significantly decreased postoperatively (P<0.001). A significantly improvement was found in all POP-Q measures (P<0.05) while mean vaginal length was similar to the preoperative values. At 24-month follow-up, 45 women were defined as ≤ stage I, indicating a 90% objective success rate (95% CI: 81.4-98.6%). Two patients had vaginal mesh extrusion (4.0%) both treated with conservative measures. No erosions occurred at any point postoperatively. De novo dyspareunia was reported in two of the 17 cases (11.8%) who reported being sexually active at follow-up. One of the two had also mesh extrusion and with appliance of the vaginal estrogen and the office excision of the exposed mesh the symptoms were resolved, while the other was treated with vaginal estrogen. Two cases (4.0%) reported de novo incontinence and both were treated with a TOT sling (monarc AMS) procedure three months after the cystocele repair. Three cases (6.0%) reported pain vaginal pain postoperatively and again our treatment of choice was vaginal estrogen cream for 4 weeks with the addition of antinflammatories for 10 days and their symptoms resolved. CONCLUSIONS: The treatment of AVP with the use of Perigee™ TOT system can be both effective and safe. The goal is the improvement of the quality of life of the patients and is important to avoid or to keep as minimum as possible the complications. Main complications that the surgeon should bear in mind are the vaginal erosion, vaginal mesh extrusion, de novo dyspareunia, de novo incontinence and vaginal pain. Proper patient selection, the appliance vaginal estrogen cream pre- and postoperatively and following strict surgical principles are the mainstay of the success of the TOT operation. It is crucial for POP procedures to be performed by high-volume surgeons in this field, with extensive knowledge of the pelvic floor anatomy and the mesh's characteristics. Of course this is a small study and further clinical studies with larger number of patients are needed in order to further scientific evaluate the TOT operation.

Responses to mechanical and electrical stimuli are not attenuated by late pregnancy.

Pregnancy has been associated with increased pain threshold. This study investigates the responses to mechanical and electrical stimuli in pregnant and non-pregnant women. Thirty pregnant women were subjected before and four days after elective caesarean section under regional anaesthesia to mechanical and electrical stimuli on both forearms. Thirty nonpregnant women were subjected to the same stimuli at the same time points. The responses to mechanical stimuli were expressed in mm of the Visual Analogue Scale (VAS) and averaged for both forearms. The VAS scores obtained after the electrical stimuli were divided by the mA recorded when the stimulus was applied, expressed in mm/mA and averaged. The responses to mechanical stimuli recorded before and four days after application did not differ between the two groups (F = 0.884, df = 3,116, P = 0.452). In the pregnant group the VAS values before and four days after the caesarean section were 16.4 +/- 14.4 mm and 12.8 +/- 12.5 mm respectively. In the nonpregnant group the VAS values recorded four days apart were 17.5 +/- 14.3 mm and 13.4 +/- 11.9 mm respectively. The responses to electrical stimuli applied four days apart also did not differ between the two groups (F = 2.433, df = 3,116, P = 0.069). The VAS values obtained after the first and second application of the electrical stimulus were 0.914 +/- 0.606 mm/mA versus 0.586 +/- 0.410 mm/mA in the pregnant and 0.853 +/- 0.538 mm/mA versus 0.725 +/- 0.467 mm/mA in the nonpregnant group. These results, under the study conditions, do not support the hypothesis that late pregnancy is associated with increased antinociception in humans.